J Ahn1, H M Lee2, J K Lim3, C Q Pan4, M H Nguyen5, W Ray Kim5, A Mannalithara5, H Trinh6, D Chu7, T Tran8, A Min9, S Do10, H Te11, K R Reddy12, A S Lok13. 1. Division of Gastroenterology & Hepatology, Oregon Health & Science University, Portland, OR, USA. 2. Gastroenterology/Hepatology Division, Tufts Medical Center, Boston, MA, USA. 3. Digestive Diseases, Yale University, New Haven, CT, USA. 4. Department of Medicine, NYU Langone, New York, NY, USA. 5. Division of Gastroenterology & Hepatology, Stanford University, Stanford, CA, USA. 6. San Jose Gastroenterology, San Jose, CA, USA. 7. Albert Einstein College of Medicine, New York, NY, USA. 8. Department of Medicine, Cedars Sinai Medical Center, Los Angeles, CA, USA. 9. Division of Gastroenterology, Mount Sinai Beth Israel, New York, NY, USA. 10. Digestive Health Associates of Texas, Plano, TX, USA. 11. Digestive Disease Center, University of Chicago, Chicago, IL, USA. 12. Division of Gastroenterology and Hepatology, University of Pennsylvania, Philadelphia, PA, USA. 13. Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI, USA.
Abstract
BACKGROUND: Entecavir (ETV) has been shown to be safe and efficacious in randomised controlled trials in highly selected patients with hepatitis B virus (HBV) infection. AIM: To determine the safety and effectiveness of ETV in 'real-world' HBV patients in the United States (US). METHODS: Treatment-naïve HBV patients ≥18 years old who received ETV for ≥12 months between 2005 and 2013 were included in a retrospective, cohort study. Rates of ALT normalisation, undetectable HBV DNA, HBeAg and HBsAg loss/seroconversion, adverse events (AE) and clinical outcomes were evaluated. RESULTS: Of 841 patients, 658 [65% male, 83% Asian; median age 47 years] met the inclusion criteria. 36% were HBeAg+ and 9.3% cirrhotic. 89% had abnormal ALT. Baseline median HBV DNA was 5.8 log 10 IU/mL. Median duration of ETV treatment was 4 years. Rates of ALT normalisation at 1, 3 and 5 years were 37.2%, 48.7% and 56.2% in HBeAg+ and 39.6%, 46.8% and 55.6% in HBeAg- patients. HBV DNA was undetectable at 1, 3 and 5 years in 34.6%, 64.7% and 84.6% in HBeAg+ patients, and 81.9%, 90.3% and 96.2% in HBeAg patients. Five-year cumulative probability of HBeAg loss and seroconversion was 46% and 33.7% and HBsAg loss was 4.6%. ETV was discontinued due to adverse events in 1.2% of patients. Hepatic decompensation occurred in 0.8%, liver cancer in 2.7% and death in 0.6%. CONCLUSION: Entecavir treatment was safe in a large cohort of US patients, but ALT normalisation and hepatitis B virus DNA suppression rates were lower than previously reported in clinical trials.
BACKGROUND:Entecavir (ETV) has been shown to be safe and efficacious in randomised controlled trials in highly selected patients with hepatitis B virus (HBV) infection. AIM: To determine the safety and effectiveness of ETV in 'real-world' HBVpatients in the United States (US). METHODS: Treatment-naïve HBVpatients ≥18 years old who received ETV for ≥12 months between 2005 and 2013 were included in a retrospective, cohort study. Rates of ALT normalisation, undetectable HBV DNA, HBeAg and HBsAg loss/seroconversion, adverse events (AE) and clinical outcomes were evaluated. RESULTS: Of 841 patients, 658 [65% male, 83% Asian; median age 47 years] met the inclusion criteria. 36% were HBeAg+ and 9.3% cirrhotic. 89% had abnormal ALT. Baseline median HBV DNA was 5.8 log 10 IU/mL. Median duration of ETV treatment was 4 years. Rates of ALT normalisation at 1, 3 and 5 years were 37.2%, 48.7% and 56.2% in HBeAg+ and 39.6%, 46.8% and 55.6% in HBeAg- patients. HBV DNA was undetectable at 1, 3 and 5 years in 34.6%, 64.7% and 84.6% in HBeAg+ patients, and 81.9%, 90.3% and 96.2% in HBeAgpatients. Five-year cumulative probability of HBeAg loss and seroconversion was 46% and 33.7% and HBsAg loss was 4.6%. ETV was discontinued due to adverse events in 1.2% of patients. Hepatic decompensation occurred in 0.8%, liver cancer in 2.7% and death in 0.6%. CONCLUSION:Entecavir treatment was safe in a large cohort of US patients, but ALT normalisation and hepatitis B virus DNA suppression rates were lower than previously reported in clinical trials.
Authors: María Buti; Rosa Maria Morillas; Martín Prieto; Moisés Diago; Juan Pérez; Ricard Solà; Lucía Bonet; Antonio Palau; Milagros Testillano; Javier García-Samaniego; Manuel Rodríguez Journal: Eur J Gastroenterol Hepatol Date: 2012-05 Impact factor: 2.566
Authors: Yun-Fan Liaw; I-Shyan Sheen; Chuan-Mo Lee; Ulus Salih Akarca; George V Papatheodoridis; Florence Suet-Hing Wong; Ting-Tsung Chang; Andrzej Horban; Chia Wang; Peter Kwan; Maria Buti; Martin Prieto; Thomas Berg; Kathryn Kitrinos; Ken Peschell; Elsa Mondou; David Frederick; Franck Rousseau; Eugene R Schiff Journal: Hepatology Date: 2010-10-27 Impact factor: 17.425
Authors: Michael P Manns; Ulus S Akarca; Ting-Tsung Chang; William Sievert; Seung Kew Yoon; Naoky Tsai; Albert Min; Andreas Pangerl; Suzanne Beebe; Miao Yu; Suchat Wongcharatrawee Journal: Expert Opin Drug Saf Date: 2012-01-11 Impact factor: 4.250
Authors: Christian M Lange; Jörg Bojunga; Wolf Peter Hofmann; Katrin Wunder; Ulrike Mihm; Stefan Zeuzem; Christoph Sarrazin Journal: Hepatology Date: 2009-12 Impact factor: 17.425
Authors: J-L Hou; J-D Jia; L Wei; W Zhao; Y M Wang; M Cheng; X Tang; D-M Tan; H Ren; H Tang; D Cohen; C Llamoso Journal: J Viral Hepat Date: 2013-11 Impact factor: 3.728
Authors: Hannah M Lee; Joseph Ahn; W Ray Kim; Joseph K Lim; Mindie Nguyen; Calvin Q Pan; Donghee Kim; Ajitha Mannalithara; Helen Te; Huy Trinh; Danny Chu; Tram Tran; Jocelyn Woog; Anna S Lok Journal: Dig Dis Sci Date: 2018-09-20 Impact factor: 3.199
Authors: Kelly A Borges; Jianliang Dai; Neehar D Parikh; Myron Schwartz; Mindie H Nguyen; Lewis R Roberts; Alex S Befeler; Sudhir Srivastava; Jo Ann Rinaudo; Ziding Feng; Jorge A Marrero; K Rajender Reddy Journal: Contemp Clin Trials Date: 2018-11-12 Impact factor: 2.226
Authors: Mar Riveiro-Barciela; David Tabernero; José L Calleja; Sabela Lens; María L Manzano; Francisco Gea Rodríguez; Javier Crespo; Belén Piqueras; Juan M Pascasio; Carmen Comas; Maria L Gutierrez; Alberto Aguirre; Emilio Suárez; Javier García-Samaniego; Miguel Rivero; Doroteo Acero; Miguel Fernandez-Bermejo; Diego Moreno; Pilar Sánchez-Pobre; Beatriz de Cuenca; J J Moreno-Palomares; Rafael Esteban; Maria Buti Journal: Dig Dis Sci Date: 2017-01-11 Impact factor: 3.199
Authors: Joseph Ahn; Joseph K Lim; Hannah M Lee; Anna S Lok; Mindie Nguyen; Calvin Q Pan; Ajitha Mannalithara; Helen Te; K Rajender Reddy; Huy Trinh; Danny Chu; Tram Tran; Daryl Lau; Truong-Sinh Leduc; Albert Min; Loc Trong Le; Ho Bae; Sang Van Tran; Son Do; Hie-Won L Hann; Clifford Wong; Steven Han; Anjana Pillai; James S Park; Myron Tong; Steve Scaglione; Jocelyn Woog; W Ray Kim Journal: Am J Gastroenterol Date: 2016-06-21 Impact factor: 10.864
Authors: L H Nguyen; J Hoang; N H Nguyen; V D Vu; C Wang; H N Trinh; J Li; J Q Zhang; M H Nguyen Journal: Aliment Pharmacol Ther Date: 2016-07-01 Impact factor: 8.171